CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Dr. Shah Discusses Potential of bb21217 in Multiple Myeloma

January 9th 2019

Nina Shah, MD, associate professor of medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the potential of bb21217 in the treatment of patients with multiple myeloma.

CAR T-Cell Therapy in Other Disease Settings and Beyond

January 8th 2019

Is the Community Setting Ready for CAR T-Cell Therapy?

January 8th 2019

Outpatient Administration Potential of CAR T-Cell Therapy

January 8th 2019

CAR T-Cell Therapy: Understanding Indicators of Response

January 8th 2019

CAR T-Cell Therapy in Adult Acute Lymphoblastic Leukemia

January 8th 2019

CAR T-Cell Therapy's Role in the ALL Treatment Paradigm

January 8th 2019

Considering Differences Among CAR T-Cell Therapies

January 8th 2019

Practical Applications of CAR T-Cell Therapy in ALL

January 8th 2019

Tisagenlecleucel for Pediatric and Young Adult ALL

January 8th 2019

Potential Use of CAR T-Cell Therapy Earlier in Sequencing

January 8th 2019

Optimizing the Use of CAR T-Cell Therapy in Lymphoma

January 8th 2019

CAR T-Cell Therapy: Real-World Applications

January 8th 2019

A Historic Perspective on High-Risk Lymphoma Management

January 8th 2019

Clinical Trial Data for Respective CAR T-Cell Therapies

January 8th 2019

Despite Progress With CAR T-Cell Therapy, Transplant Retains Role in Myeloma

January 3rd 2019

Deepu Madduri, MD, discusses the status of transplant for eligible patients and the developments that are being made with CAR T-cell therapy in multiple myeloma.

Lead Researcher Highlights Tisagenlecleucel Benefit in Younger Leukemia Patients

January 3rd 2019

Stephen Grupp, MD, PhD, discusses the updated analysis of the ELIANA trial and its implications for pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia.

Dr. Grupp on the Optimal Setting of CAR T-Cell Therapy in ALL

January 2nd 2019

Stephan Grupp, MD, PhD, director, Cancer Immunotherapy Program, director, Translational Research for the Center for Childhood Cancer Research, medical director, Stem Cell Laboratory, Children’s Hospital of Philadelphia, discusses the placement of chimeric antigen receptor (CAR) T-cell therapy in the treatment of patients with acute lymphoblastic leukemia (ALL).

Dr. Ghobadi on Ways of Reducing the Cost of CAR T-Cell Therapy

December 20th 2018

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses ways of reducing the cost of chimeric antigen receptor (CAR) T-cell therapy.

Dr. Gauthier on Potential for CAR T Cells in CLL

December 11th 2018

Jordan Gauthier, MD, MSc, senior clinical research fellow, Fred Hutchinson Cancer Research Center, discusses the potential for chimeric antigen receptor T-cell therapy in the treatment of chronic lymphocytic leukemia.